Agreed. It isn’t clear what the issue is here.
If the research protocol states 3 years of data collection it’s technically unethical, without submitting an amendment, to collect data beyond 3 years as the patient hasn’t agreed to this. Sure, in hindsight the data should have been collected for longer but at the time of study design 3 years probably seemed appropriate. It’s really difficult to say how long to follow up - forever? Sure, but would be financially unfeasible.
We do have a yellow carding system in the UK - the medicine and health regulatory authority (MHRA) run this and it’s for submission of adverse drug reactions as well device issues. But again, not sure how helpful it would have been for the instances of participant death after 3 years. Seems harsh on the doctors who carried out the research, unless I’m not reading this correctly.